ID   5637 subclone 1A6
AC   CVCL_6344
SY   5637 (subclone 1A6); 1A6
DR   CLO; CLO_0001149
DR   ATCC; CRL-2742
DR   cancercelllines; CVCL_6344
DR   Cosmic; 2037945
DR   GEO; GSM136246
DR   GEO; GSM827286
DR   GEO; GSM1374374
DR   LINCS_LDP; LCL-1703
DR   Progenetix; CVCL_6344
DR   Wikidata; Q54582656
RX   Patent=US6114166;
RX   PubMed=20215515;
RX   PubMed=24018021;
RX   PubMed=29732388;
CC   Group: Patented cell line.
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-556.
CC   Sequence variation: Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Discontinued: ATCC; CRL-2742; true.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): ATCC=CRL-2742
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 9
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 16,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0126 ! 5637
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 30
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon, Tahlita C.M.
RA   de Jong, Florus Christiaan
RA   Costello, James C.
RA   Theodorescu, Dan
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg, S. Michael
RA   Mohapatra, Gayatry
RA   Rivera, Miguel N.
RA   Winokur, Daniel
RA   Greninger, Patricia
RA   Nitta, Mai
RA   Sadow, Peter M.
RA   Sooriyakumar, Gaya
RA   Brannigan, Brian W.
RA   Ulman, Matthew J.
RA   Perera, Rushika M.
RA   Wang, Rui
RA   Tam, Angela
RA   Ma, Xiao-Jun
RA   Erlander, Mark
RA   Sgroi, Dennis C.
RA   Rocco, James W.
RA   Lingen, Mark W.
RA   Cohen, Ezra E.W.
RA   Louis, David Neil
RA   Settleman, Jeffrey
RA   Haber, Daniel Arie
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory, Yves
RA   Beukers, Willemien
RA   Sagrera, Ana
RA   Flandez, Marta
RA   Marques, Miriam
RA   Marquez, Mirari
RA   van der Keur, Kirstin A.
RA   Dyrskjot, Lars
RA   Lurkin, Irene
RA   Vermeij, Marcel
RA   Carrato, Alfredo
RA   Lloreta, Josep
RA   Lorente, Jose A.
RA   Carrillo-de-Santa-Pau, Enrique
RA   Masius, Roy Geordi
RA   Kogevinas, Manolis
RA   Steyerberg, Ewout Willem
RA   van Tilborg, Angela A.G.
RA   Abas, Cheno
RA   Orntoft, Torben Falck
RA   Zuiverloon, Tahlita C.M.
RA   Malats, Nuria
RA   Zwarthoff, Ellen C.
RA   Real, Francisco X.
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   Patent=US6114166;
RA   Welte, Karl
RA   Platzer, Erich
RA   Gabrilove, Janice Lester
RA   Mertelsmann, Roland
RA   Moore, Malcolm A.S.
RT   "Human pluripotent hematopoietic colony stimulating factor and cell
RT   line producing same.";
RL   Patent number US6114166, 05-Sep-2000.
//